Ticker: Sarepta reports death in drug trial; Google makes $32B cybersecurity deal
Cambridge-based Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for muscular dystrophy, sending company shares plummeting in morning trading. The young man died of acute liver injury, a known side effect, Sarepta said in a statement. But the company said the “severity” of the patient’s case had not…
